Tom Powles, Professor at the University of London, shared a post on X:
“The muscle invasive bladder cancer session AUC3 discussed perioperative durvalumab + ctDNA are changing the disease. Also, pCR of >50% is expected with EVP. Bladder sparing approaches after EVP is likely to be the standard of care if this is the case.”
